Medical Device News Magazine

Successful Diagnostics of Antibodies: Optics Balzers AG Has Further Developed Optical Dielectric Filters in the UV Spectrum

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

Optics Balzers reports: Short-wave light, ranging from 100 to 400nm in the UV spectrum, has the ability to fight pathogens. In medical fields, this property is commonly used to combat germs, bacteria and viruses. In fact, studies have shown that when irradiated with short-wave UV-C light more than 95% of viruses become ineffective.

Optical filters with transmission of over 95%

Short-wave light is also used in virological diagnostics. Antibodies are marked with a fluorochrome, and when stimulated by a defined UV radiation, can then be visualized. Specially matched optical filters are used to separate excitation and emission wavelengths.

The steepness of the edge found at the transition between these spectral ranges is characteristic of the high quality of our filters. On a spectrum of T < 0.01% to T > 95% an edge steepness of approximately 2 to 5nm is required. To achieve this level of precision the filters at Optics Balzers AG are manufactured using sputtering process technology to create these dielectric coatings. In addition to the spectral accuracy, the environmental stability of the filter is a decisive factor in this coating process.

Specific adaptation of filters possible

The SP270 short pass filter from Optics Balzers shows the characteristic spectral course of a corresponding filter for the excitation of fluorophoric substances. The highest possible transmission rate is guaranteed, with a pass range of around 270nm. In addition, undesired excitations of up to 480nm are suppressed in the long-wave blocking range.

The fluorophoric substances stimulated by UV radiation emit long-wave signals above 275nm. The BP310-390 long-pass filter used here enables the detection of these emitted signals. The BP310-390 filter shown in the image below has an average transmission of > 95% for signal detection, within the range of 330nm to 390nm.

Our optical filters, which enable the excitation and the detection of signals in the UV range, can be adapted to specific substances. Based on the appropriate filters, a wide range of relevant information from the UV spectrum can be obtained for further medical diagnosis.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”